Ménière’s Disease Symposium

Friday, February 21 | 2 to 6pm | Renaissance Orlando at SeaWorld

The Ménière’s Disease Symposium was sponsored by the American Hearing Research Foundation and Hearing Health Foundation. Hosted by the Association for Research in Otolaryngology (ARO), it was held on the Friday before the 48th Annual ARO MidWinter Meeting in Orlando.

Please see an overall summary of the event here, with a detailed summary below.

On the YouTube player, click “cc” for captions. Click here for full transcript. A few video edits are to come.

The symposium aimed to spur collaborative thinking and projects among Ménière’s disease researchers and clinicians to stimulate advances in better understanding and treating Ménière's disease, a chronic inner ear condition affecting balance and hearing. HHF and its partners are committed to supporting research to improve the quality of life for hundreds of thousands of people worldwide living with the condition.

Talks and panel discussions were research-focused and the symposium was intended primarily for investigators and clinicians. Insights and findings arising from the symposium will be shared by HHF and its partners with the wider community as appropriate.

If you were able to attend, we welcome feedback through this brief survey. Questions? Please email info@hhf.org.


Organizational Sponsors


Sponsors

 

Organizational Partners


Jump to:
Overview
Detailed Summary
Schedule
Presenter Bios

For details please refer to the captioned video, with timestamps, and the full transcript.

Patient Perspective 

Heather Davies | VeDA (Vestibular Disorders Association) ambassador, author, podcast host

• Davies shares her personal experience with Ménière's disease, describing severe episodes of vertigo, tinnitus, and hearing issues that forced her to leave her nursing career and drastically change her life.

• After being encouraged to "dream another dream," she found purpose by creating the Ménière's Muse podcast, which provides a platform for vestibular disorder patients to share their stories and build community.

• Despite describing Ménière's as both a "blessing and a curse," Davies emphasizes the importance of finding hope, adapting to new limitations, and recognizing that medical research provides critical support to those suffering from vestibular disorders.

History of Ménière’s Disease 

Robin Bigelow, M.D. | The House Institute Foundation

• Prosper Ménière revolutionized understanding of vertigo in 1861 by linking it to inner ear disease rather than brain disorders, describing what became known as Ménière's disease with symptoms of fluctuating hearing loss, tinnitus, and dizzy spells.

• Over the past 150 years, numerous treatments for Ménière's disease have been attempted—from early remedies like bloodletting, leeches, and iodine to various surgical interventions including endolymphatic sac surgery, nerve sectioning, and labyrinthectomy—reflecting the challenging nature of treating this condition.

Treatment: State of the Art Clinical Care; Clinical Unmet Needs

Habib Rizk, M.D. | Medical University of South Carolina (MUSC)

• Current clinical care for Ménière's disease lacks evidence-based treatments, with dietary modifications, diuretics, and betahistine commonly used despite limited scientific support, though clinicians observe patient improvements that suggest effectiveness beyond placebo effects.

• There's significant overlap between Ménière's disease and vestibular migraine, with research suggesting multiple subclassifications or "endophenotypes" of Ménière's disease that may require different treatment approaches, including those with migraine features.

• Clinical trials for Ménière's disease face significant challenges including significant placebo response rates, inconsistent outcome measures, and the need for“better trial designs that account for disease subtypes and fluctuating symptoms, with researchers suggesting alternative approaches like the STAR*D design used in depression clinical trials, to maximize recruitment accrual, compliance, and longitudinal follow-up.

Migraine and Ménière’s Disease

Jeffrey Sharon, M.D. | University of California, San Francisco (UCSF)

• Migraine affects 10-15% of the global population and shows surprising connections with vestibular disorders, with more than half of Ménière's disease patients meeting criteria for migraine, suggesting a relationship that dates back to Prosper Ménière's original observations in 1861.

• Research shows biological links between migraine and vestibular function through CGRP (calcitonin gene-related peptide), a neuroinflammatory peptide expressed in the vestibular periphery that affects balance in animal models, with preliminary clinical trial data showing CGRP-blocking drugs may reduce dizziness symptoms.

• There are multiple lines of evidence connecting migraine and Ménière's disease: epidemiological overlap, shared symptoms and triggers, correlation in symptom laterality, potential pathophysiological mechanisms involving trigeminal nerve innervation of inner ear blood vessels, and genetic patterns in affected families. This suggests that exploring migraine medications as treatments for Ménière's disease is warranted.

Imaging/MRI

Amy Juliano, M.D. | Mass Eye and Ear

• MRI imaging techniques have evolved to visualize endolymphatic hydrops in Ménière's disease patients by using contrast agents that permeate into perilymph but not endolymph, allowing radiologists to objectively identify enlarged cochlear ducts, saccules, and utricles as visible signs of the condition.

• Research has identified two distinct endotypes of Ménière's disease: hypoplastic (where the endolymphatic sac never developed properly) and degenerative (where the endolymphatic sac developed but then degenerated), which can be distinguished on imaging by examining the vestibular aqueduct angle or the thickness of retrolabyrinthine bone.

• Modern radiological reports for Ménière's disease patients now include assessment of endolymphatic structure sizes, perilymph enhancement (which correlates with sensorineural hearing loss), and anatomical features that help subtype the disease, providing valuable prognostic information for treatment planning.

Panel Discussion: Management of Ménière’s/Patient Stories

Moderated by John Oghalai, M.D. (USC) with Habib Rizk, M.D. (MUSC), Jeffrey Sharon, M.D. (UCSF), William Slatterly, M.D. (House Institute Foundation)

• The panelists discussed approaches to diagnosing and treating Ménière's disease, emphasizing the importance of careful history-taking to distinguish "classic" Ménière's (vertigo episodes with concurrent hearing loss, tinnitus, and aural fullness) from other conditions like vestibular migraine.

• First-line treatments typically include low-salt diet, migraine diet, and diuretics, with steroids considered for persistent symptoms or significant hearing fluctuations; the panelists had varying practices regarding when to order MRIs and vestibular testing.

• Several potential triggers or contributing factors were discussed, including barometric pressure changes, allergies, stress, and genetic factors, with some panelists routinely performing genetic testing in challenging cases.

• The experts emphasized the need for better research on Ménière's disease subtypes and etiology, with consensus that it's likely multiple different conditions with similar presentations, requiring more precise diagnosis and individualized treatment approaches.

Molecular Basis

Andreas Eckhard, M.D. | Harvard Medical School/Mass Eye and Ear

• Evidence that endolymphatic hydrops may be a compensatory response to injury rather than the cause of symptoms challenges the traditional view of Ménière's disease as primarily a fluid pressure disorder.

• Research shows that the endolymphatic sac, which makes up about a third to half of the inner ear's epithelial surface, is consistently damaged in Ménière's disease patients, and this damage represents a major injury to the inner ear.

• This suggests a new model where Ménière's disease follows a pattern of maladaptive progression similar to chronic kidney disease: with initial injury, compensatory mechanisms (including cell proliferation in hydropic membranes), a phase of fluctuating function, and eventual burnout.

Genetics

Jose Antonio Lopez-Escamez, M.D., Ph.D. | University of Sydney, Australia

• Ménière's disease can be seen not a single disease but has multiple subtypes, including three immune response-related subgroups (autoimmune, autoinflammatory, and IgE-associated) that can be identified through measuring cytokines and IgE in blood tests, while approximately 40% of patients may have a genetic origin with normal immune responses.

• Genetic research has identified about 20 genes associated with familial Ménière's disease, with the three most common being OTOG (encoding otogelin), MYO7A (encoding myosin), and TECTA (encoding alpha-tectorin), and a newly discovered gene GJD3 (encoding Connexin 31.9), with most genetic cases involving the stereocilia and tectorial membrane.

• These findings suggest Ménière's disease often results from a combination of genetic predisposition (a "fragile ear") plus environmental triggers like noise exposure, with approximately 9% of European cases being familial, and an estimated 28% of sporadic cases potentially having genetic origins as well.

Immunology and Ménière’s Disease

Andrea Vambutas, M.D. | Northwell Health, New York

• A challenge to traditional classifications of Ménière's disease is that it may exist on a continuum with autoimmune inner ear disease, with some cases potentially being autoinflammatory rather than autoimmune in nature.

• Research shows different cytokine profiles among patients, particularly finding that corticosteroid-responsive patients have high TNF levels that drop with treatment, while corticosteroid-resistant patients have low TNF but high IL-1 levels and may respond to anakinra (an IL-1 receptor antagonist).

• A phase two clinical trial using anakinra for corticosteroid-resistant Ménière's disease patients is being conducted, with preliminary results showing promising signals, building on their earlier research that found a 70% response rate in autoimmune inner ear disease patients treated with anakinra.

Social and Psychological Triggers

Joanna Wolfson, Ph.D. | New York University Langone Health 

• The significant psychological impact of Ménière's disease is that 50-60% of patients experience anxiety or depression due to factors like the traumatic and unpredictable nature of symptoms, uncertainty about future progression, and the "hidden disability" quality that others cannot see or understand.

• The presentation explains how Ménière's symptoms and psychological distress create a vicious cycle (symptoms trigger fight-or-flight responses that can exacerbate dizziness and other symptoms), and recommends psychological interventions including explaining the stress-symptom cycle, teaching relaxation techniques, using cognitive-behavioral therapy approaches to reframe thoughts, and helping patients gradually return to enjoyable activities with an acceptance of their "new normal."

Panel Discussion: Barriers to Ménière’s Disease Research

Moderated by Divya Chari, M.D. (Harvard Medical School) with Andrea Vambutas, M.D. (Northwell Health), Andreas Eckhard, M.D. (Harvard/Mass Eye and Ear), Jose Antonio Lopez-Escamez, M.D., Ph.D. (University of Sydney)

• The panelists emphasized the need for more precise patient selection using biomarkers (such as IL-1 beta and TNF levels) to differentiate Ménière's disease from similar conditions like vestibular migraine and to identify distinct subgroups within Ménière's patients.

• Clinical trials for Ménière's disease face significant challenges due to the disease's fluctuating nature and significant placebo response rates, making it difficult to distinguish treatment effects from the natural course of the disease.

• Research has evolved from viewing Ménière's as a purely mechanical problem to understanding its molecular and genetic components, with significant advances in identifying familial clusters and developing humanized transgenic animal models.

• Despite affecting relatively few people, Ménière's disease doesn't qualify for "rare disease" funding benefits, creating additional obstacles for research funding and drug development.

Part 1: Clinical Topics

Starts 2pm ET

Patient Perspective

Heather Davies

VeDA (Vestibular Disorders Association) ambassador, author, podcast host

History of Ménière’s Disease

Robin Bigelow, M.D.

The House Institute Foundation

Treatment: State of the Art Clinical Care; Clinical Unmet Needs

Habib Rizk, M.D.

Medical University of South Carolina (MUSC)

Migraine and Ménière’s Disease

Jeffrey Sharon, M.D.

University of California, San Francisco (UCSF)

Imaging/MRI

Amy Juliano, M.D.

Mass Eye and Ear

Panel Discussion: Management of Ménière’s/Patient Stories

Habib Rizk, M.D. (MUSC), Jeffrey Sharon, M.D. (UCSF), William Slatterly, M.D. (House Institute Foundation)


Break 4pm ET


Part 2: Lab Science, Knowledge Gaps

Starts 4:15pm ET

Molecular Basis

Andreas Eckhard, M.D.

Harvard Medical School/Mass Eye and Ear

Genetics

Jose Antonio Lopez-Escamez, M.D., Ph.D.

University of Sydney, Australia

Immunology and Ménière’s Disease

Andrea Vambutas, M.D.

Northwell Health, Long Island, New York

Social and Psychological Triggers

Joanna Wolfson, Ph.D.

NYU Langone Health 

Panel Discussion: Barriers to Ménière’s Disease Research

Andrea Vambutas, M.D. (Northwell Health), Andreas Eckhard, M.D. (Harvard/Mass Eye and Ear), Jose Antonio Lopez-Escamez, M.D., Ph.D. (University of Sydney)


Networking Reception

From 6:15 to 8pm ET

Beverages and hearty appetizers

Schedule as of November 11, 2024 (subject to change).


Jump to:
Overview
Detailed Summary
Schedule
Presenter Bios


Part 1: Clinical Topics

Patient Perspective: Heather Davies

Heather Davies’ Ménière’s journey began with six months of relentless vertigo, hyperacusis, and an overwhelming array of symptoms, causing her to make the difficult decision to step away from an 18-year nursing career, and ultimately spiraling into a deep depression. Leaning on the vestibular community she was reminded of her dreams, which fueled a determination to figure out how to live her best life despite symptoms. This journey transformed Davies into the inspiring host of the Ménière’s Muse podcast, a testament to the healing power of connection. Through her podcast and volunteer efforts with VeDA (Vestibular Disorders Association), she is a vital voice in the vestibular community, sowing seeds of hope by sharing her own story and encouraging others to share theirs.

History of Ménière’s Disease: Robin Bigelow, M.D.

Robin Bigelow, M.D., is a neurotologist treating the full spectrum of otologic and neurotologic diseases with the Summit Medical Group in Northern New Jersey. He completed his neurotology fellowship at the House Ear Institute. He attended Johns Hopkins for both medical school and his residency in otolaryngology–head and neck surgery. His main research interests include understanding the history of ear disease and treatments, including Méniere’s Disease, as well as societal impacts of hearing loss and vestibular dysfunction. 

Treatment: State of the Art Clinical Care; Clinical Unmet Needs: Habib Rizk, M.D.

Habib G. Rizk, M.D., grew up in Beirut, Lebanon, where he obtained his medical degree from Saint Joseph University and completed an otolaryngology–head and neck surgery residency at Hôtel-Dieu de France Hospital in Beirut. After a one-year otologic medicine and surgery fellowship under the mentorship of Michael Teixido, M.D., and a two-year neurotology fellowship at the Medical University of South Carolina, he joined the faculty at MUSC. Dr. Rizk is an associate professor of otolaryngology–head and neck surgery and is the director of the multidisciplinary vestibular clinic. He is on the board of directors and is the current president of VeDA. He is a member of the Bárány Society and a fellow of the American Neurotology Society. Dr. Rizk is also a member of the American Balance Society and of the otology and neurotology education committee of the American Academy of Otolaryngology–Head and Neck Surgery. 

Migraine and Ménière’s Disease: Jeffrey Sharon, M.D.

Jeffrey Sharon, M.D., is an associate professor of otology, neurotology, and skull base surgery at University of California, San Francisco. He is also the director of the Balance and Falls Center. He completed a residency in otolaryngology–head and neck surgery at Washington University in St. Louis and a fellowship in neurotology at Johns Hopkins. His research is on the vestibular system with a focus on clinical and translational projects to improve care for those with vestibular disorders. Dr. Sharon has a special interest in vestibular migraine, where he has developed and validated the first disease-specific, patient-reported outcome measure, and also completed the first randomized clinical trial of a CGRP blocking drug.

Imaging/MRI: Amy Juliano, M.D.

Amy Juliano, M.D., is a head and neck radiologist, director of research and academic affairs, and fellowship program director for the department of radiology at Mass Eye and Ear and an associate professor of radiology at Harvard Medical School. She completed her diagnostic radiology residency at Brigham and Women’s Hospital and neuroradiology fellowship at Brigham/Boston Children’s Hospital. She received her medical doctorate at the University of Pennsylvania School of Medicine and a master’s degree in Physics at Harvard University. Dr. Juliano is senior editor for the AJNR Head and Neck section, chair of the ACR Appropriateness Criteria Committee Head and Neck Panel, and chair of the ACR NI-RADS Committee. She serves as chair of the ASNR International Collaborations Committee, chair of the education committee, and executive committee member of the ASHNR, and president of the Eastern Neuroradiological Society. She is on the Diagnostic Radiology and Neuroradiology Certification board examination question writing committees for the American Board of Radiology. Dr. Juliano is one of the four cofounders and panelists of “T Bone Time,” a webinar series that began in 2020 for sharing and discussion of interesting temporal bone cases.

Panel Discussion: Management of Ménière’s/Patient Stories: Habib Rizk, M.D., Jeffrey Sharon, M.D., and William Slatterly, addition TBD 

Part 2: Lab Science, Knowledge Gaps

Molecular Basis: Andreas Eckhard, M.D.

Andreas Eckhard, M.D., obtained his medical degree from the University of Tübingen Medical School and the Hearing Research Center, Tübingen, in Germany. He trained as a postdoctoral fellow in the otopathology laboratory at Mass Eye and Ear before completing his clinical training in otolaryngology at the University Hospital Zurich in Switzerland. As a resident and junior consultant, he completed clinical work at the Interdisciplinary Centers for Vertigo and Balance Disorders in Munich and Zurich, respectively. He is an assistant professor of otolaryngology–head and neck surgery at Harvard Medical School, and co-director, Otopathology Laboratory, at Mass Eye and Ear. In both his research and clinical work, Dr. Eckhard has pursued a strong focus on vestibular disorders. His research interests are the cellular and molecular pathomechanisms of inner-ear diseases, foremost Ménière’s disease, with special interest in the pathogenic roles of non-sensory supporting cells. His group seeks to develop and implement new diagnostic and therapeutic approaches for vestibular disorders, utilizing methods ranging from basic animal models to translational patient-based approaches, with a dedicated focus on integrating human otopathology research. Dr. Eckhard’s clinical work is strongly informed by his research and revolves around diagnosing and managing patients with vestibular and combined vestibular and auditory symptoms.

Genetics and Ménière’s Disease: Jose Antonio Lopez-Escamez, M.D., Ph.D.

Professor Lopez-Escamez is an international leader in genetics of Ménière’s disease (MD) and tinnitus, ranked in the Stanford World Top 2% Scientists in 2021–2023. He has over 175 papers in top scientific journals with over 8,900 citations in Google Scholar. He has been granted over $7M in competitive funding in Europe and currently leads the Ménière’s Disease Neuroscience Research Program at the University of Sydney. His work during the past 10 years has redefined the condition (2015 MD diagnostic criteria); identified five clinical variants, including autoimmune and familial MD; discovered the main genes involved in familial MD in European descendant population (OTOG, MYO7A, TECTA); and reclassified MD clinical variants, according to cytokine profile and genetic data, leading to a better understanding of the genetic contribution and inflammatory process in MD. In addition his collaborative work in several European consortia (TINNET, ESIT, TIGER, UNITI) has also lead to seminal contributions in the tinnitus heritability and the discovery of several genes in patients with severe tinnitus (ANK2, TSC2). Professor Lopez-Escamez has supervised13 International Ph.D. and 27 master’s students at the University of Granada in Spain. His mentees are enrolled as postdoctoral researchers in top ranked universities including University of Edinburgh, University of Cambridge, University College London, Harvard University, and Karolinska Institute. 

Immunology and Ménière’s Disease: Andrea Vambutas, M.D.

Andrea Vambutas, M.D., FACS, oversees the quality and delivery of Head and Neck Services at Northwell Health. She also serves as chair of otolaryngology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. Dr. Vambutas is a nationally recognized leader in immune-mediated hearing loss. In addition to her clinical and academic titles, Dr. Vambutas is an investigator in the Center for Autoimmune & Musculoskeletal Disorders at the Feinstein Institutes for Medical Research. Her laboratory is focused on understanding the molecular mechanisms of immune mediated hearing loss. She is a regular reviewer for the National Institutes of Health and other grant agencies. She has been elected to a number of national positions, including the board of directors of the American Auditory Society; the Education Committee of the American Neurotology Society; the CORE Grant Committee of the American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS); and the Research Advisory Board of the American Otological Society.

Social and Psychological Triggers: Joanna Wolfson, Ph.D.

Joanna Wolfson, Ph.D., ABPP, is a senior psychologist on the Adult Outpatient service at Rusk Rehabilitation, New York University Langone Health, and clinical assistant professor of Rehabilitation Medicine at the NYU Grossman School of Medicine. She holds a doctorate in clinical psychology from Fairleigh Dickinson University in New Jersey, completed her internship at NYU Rusk, and her postdoctoral fellowship at the Manhattan VA in health psychology and primary care. She is board certified in clinical health psychology. Dr. Wolfson provides individual and group psychotherapy to patients with a wide range of medical presentations, including vestibular conditions. She co-leads a vestibular stress management group, which has been running for the past nine years. She also supervises interns in the field of health psychology and presents on topics including integrated healthcare, motivational interviewing, and health anxiety.

Panel Discussion: Barriers to Ménière’s Disease Research: Andrea Vambutas, M.D., Andreas Eckhard, M.D., Jose Antonio Lopez-Escamez, M.D., Ph.D.


 Post-Event Survey